|
1
|
Jemal A, Siegel R, Xu J and Ward E: Cancer
statistics, 2010. CA Cancer J Clin. 60:277–300. 2010. View Article : Google Scholar
|
|
2
|
Cersosimo RJ: Lung cancer: a review. Am J
Health Syst Pharm. 59:611–642. 2002.PubMed/NCBI
|
|
3
|
Fry WA, Phillips JL and Menck HR: Ten-year
survey of lung cancer treatment and survival in hospitals in the
United States: a national cancer data base report. Cancer.
86:1867–1876. 1999.PubMed/NCBI
|
|
4
|
Sawaya R: Considerations in the diagnosis
and management of brain metastases. Oncology (Williston Park).
15:1144–1165. 2001.PubMed/NCBI
|
|
5
|
Langley RR and Fidler IJ: Tumor cell-organ
microenvironment interactions in the pathogenesis of cancer
metastasis. Endocr Rev. 28:297–321. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Fidler IJ: The pathogenesis of cancer
metastasis: the ‘seed and soil’ hypothesis revisited. Nat Rev
Cancer. 3:453–458. 2003.
|
|
7
|
Strieter RM, Belperio JA, Burdick MD,
Sharma S, Dubinett SM and Keane MP: CXC chemokines: angiogenesis,
immunoangiostasis, and metastases in lung cancer. Ann NY Acad Sci.
1028:351–360. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Singh S, Sadanandam A and Singh RK:
Chemokines in tumor angiogenesis and metastasis. Cancer Metastasis
Rev. 26:453–467. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zlotnik A, Burkhardt AM and Homey B:
Homeostatic chemokine receptors and organ-specific metastasis. Nat
Rev Immunol. 11:597–606. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
10
|
Phillips RJ, Burdick MD, Lutz M, Belperio
JA, Keane MP and Strieter RM: The stromal derived
factor-1/CXCL12-CXC chemokine receptor 4 biological axis in
non-small cell lung cancer metastases. Am J Respir Crit Care Med.
167:1676–1686. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Takanami I: Overexpression of CCR7 mRNA in
nonsmall cell lung cancer: correlation with lymph node metastasis.
Int J Cancer. 105:186–189. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Marchesi F, Piemonti L, Fedele G, et al:
The chemokine receptor CX3CR1 is involved in the neural tropism and
malignant behavior of pancreatic ductal adenocarcinoma. Cancer Res.
68:9060–9069. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Andre F, Cabioglu N, Assi H, et al:
Expression of chemokine receptors predicts the site of metastatic
relapse in patients with axillary node positive primary breast
cancer. Ann Oncol. 17:945–951. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Marshall HM, Leong SC, Bowman RV, Yang IA
and Fong KM: The science behind the 7th edition Tumour, Node,
Metastasis staging system for lung cancer. Respirology. 17:247–260.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Dhillon T, Mauri FA, Bellezza G, et al:
Overexpression of the mammalian target of rapamycin: a novel
biomarker for poor survival in resected early stage non-small cell
lung cancer. J Thorac Oncol. 5:314–319. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Shi SR, Key ME and Kalra KL: Antigen
retrieval in formalin-fixed, paraffin-embedded tissues: an
enhancement method for immunohistochemical staining based on
microwave oven heating of tissue sections. J Histochem Cytochem.
39:741–748. 1991. View Article : Google Scholar
|
|
17
|
Andreasson U, Ek S, Merz H, et al: B cell
lymphomas express CX3CR1 a non-B cell lineage adhesion molecule.
Cancer Lett. 259:138–145. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
White ES, Flaherty KR, Carskadon S, et al:
Macrophage migration inhibitory factor and CXC chemokine expression
in non-small cell lung cancer: role in angiogenesis and prognosis.
Clin Cancer Res. 9:853–860. 2003.PubMed/NCBI
|
|
19
|
Burger M, Glodek A, Hartmann T, et al:
Functional expression of CXCR4 (CD184) on small-cell lung cancer
cells mediates migration, integrin activation, and adhesion to
stromal cells. Oncogene. 22:8093–8101. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hartmann TN, Burger JA, Glodek A, Fujii N
and Burger M: CXCR4 chemokine receptor and integrin signaling
co-operate in mediating adhesion and chemoresistance in small cell
lung cancer (SCLC) cells. Oncogene. 24:4462–4471. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Raynaud CM, Mercier O, Dartevelle P, et
al: Expression of chemokine receptor CCR6 as a molecular
determinant of adrenal metastatic relapse in patients with primary
lung cancer. Clin Lung Cancer. 11:187–191. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Shulby SA, Dolloff NG, Stearns ME, Meucci
O and Fatatis A: CX3CR1-fractalkine expression regulates cellular
mechanisms involved in adhesion, migration, and survival of human
prostate cancer cells. Cancer Res. 64:4693–4698. 2004. View Article : Google Scholar
|
|
23
|
Kim M, Rooper L, Xie J, Kajdacsy-Balla AA
and Barbolina MV: Fractalkine receptor CX3CR1 is expressed in
epithelial ovarian carcinoma cells and required for motility and
adhesion to peritoneal mesothelial cells. Mol Cancer Res. 10:11–24.
2012. View Article : Google Scholar
|
|
24
|
Matsubara T, Ono T, Yamanoi A, Tachibana M
and Nagasue N: Fractalkine-CX3CR1 axis regulates tumor cell cycle
and deteriorates prognosis after radical resection for
hepatocellular carcinoma. J Surg Oncol. 95:241–249. 2007.
View Article : Google Scholar
|
|
25
|
Jubb AM, Cesario A, Ferguson M, et al:
Vascular phenotypes in primary non-small cell lung carcinomas and
matched brain metastases. Br J Cancer. 104:1877–1881. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Baird AM, Gray SG and O’Byrne KJ:
Epigenetics underpinning the regulation of the CXC
(ELR+) chemokines in non-small cell lung cancer. PLoS
One. 6:e145932011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Mizuno T, Kawanokuchi J, Numata K and
Suzumura A: Production and neuroprotective functions of fractalkine
in the central nervous system. Brain Res. 979:65–70. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Hurst LA, Bunning RA, Couraud PO, et al:
Expression of ADAM-17, TIMP-3 and fractalkine in the human adult
brain endothelial cell line, hCMEC/D3, following pro-inflammatory
cytokine treatment. J Neuroimmunol. 210:108–112. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Imaizumi T, Yoshida H and Satoh K:
Regulation of CX3CL1/fractalkine expression in endothelial cells. J
Atheroscler Thromb. 11:15–21. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Nevo I, Sagi-Assif O, Meshel T, et al: The
involvement of the fractalkine receptor in the transmigration of
neuroblastoma cells through bone-marrow endothelial cells. Cancer
Lett. 273:127–139. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Yamazaki K, Sugio K, Yamanaka T, et al:
Prognostic factors in non-small cell lung cancer patients with
postoperative recurrence following third-generation chemotherapy.
Anticancer Res. 30:1311–1315. 2010.
|
|
32
|
Lee SJ, Namkoong S, Kim YM, et al:
Fractalkine stimulates angiogenesis by activating the
Raf-1/MEK/ERK- and PI3K/Akt/eNOS-dependent signal pathways. Am J
Physiol Heart Circ Physiol. 291:H2836–H2846. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Oh Y, Taylor S, Bekele BN, et al: Number
of metastatic sites is a strong predictor of survival in patients
with nonsmall cell lung cancer with or without brain metastases.
Cancer. 115:2930–2938. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Mamon HJ, Yeap BY, Janne PA, et al: High
risk of brain metastases in surgically staged IIIA non-small-cell
lung cancer patients treated with surgery, chemotherapy, and
radiation. J Clin Oncol. 23:1530–1537. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Chen AM, Jahan TM, Jablons DM, Garcia J
and Larson DA: Risk of cerebral metastases and neurological death
after pathological complete response to neoadjuvant therapy for
locally advanced nonsmall-cell lung cancer: clinical implications
for the subsequent management of the brain. Cancer. 109:1668–1675.
2007. View Article : Google Scholar
|
|
36
|
Simon GR and Turrisi A: Management of
small cell lung cancer: ACCP evidence-based clinical practice
guidelines (2nd edition). Chest. 132:S324–S339. 2007. View Article : Google Scholar
|
|
37
|
Besse B, Massard C, Haddad V, et al: ERCC1
influence on the incidence of brain metastases in patients with
non-squamous NSCLC treated with adjuvant cisplatin-based
chemotherapy. Ann Oncol. 22:575–581. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
D’Haese JG, Demir IE, Friess H and Ceyhan
GO: Fractalkine/CX3CR1: why a single chemokine-receptor duo bears a
major and unique therapeutic potential. Expert Opin Ther Targets.
14:207–219. 2010.PubMed/NCBI
|
